Molecular biology of atherosclerosis

Clinical Cases in Mineral and Bone Metabolism

Volumn 5, Issue 1, 2008, Pages 57-62

  Mannarino, Elmo ^a   Pirro, Matteo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Endothelial dysfunction; Inflammation; Lipoproteins; Microparticles; Progenitors

Indexed keywords

APOPTOSIS; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CARDIOVASCULAR RISK; DISEASE ACTIVITY; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL MICROPARTICLE; ENDOTHELIUM INJURY; HELPER CELL; HUMAN; INFLAMMATION; LIPID STORAGE; MACROPHAGE; MOLECULAR BIOLOGY; MONOCYTE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOGENESIS; SHORT SURVEY; T LYMPHOCYTE; VASCULAR SMOOTH MUSCLE;

EID: 45349094151     PISSN: 17248914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (61)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999 Jan 14;340(2):115-26.
2. Kuiper J, van Puijvelde GH, van Wanrooij EJ, et al. Immunomodulation of the inflammatory response in atherosclerosis. Curr Opin Lipidol. 2007;18:521-526.
3. Castelli WP, Anderson K, Wilson PW, et al. Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol. 1992; 2:23-28.
4. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16: 434-444.
5. Schulze PC, Lee RT. Oxidative stress and atherosclerosis.Curr Atheroscler Rep. 2005;7:242-248.
6. Bauters C, Six I, Meurice T, et al. Growth factors and endothelial dysfunction. Drugs. 1999;58:11-15.
7. Nagy JA, Dvorak AM, Dvorak HF. VEGF-A(164/165) and PIGF: roles in angiogenesis and arteriogenesis. Trends Cardiovasc Med. 2003;13:169-175.
8. Mahmoudi M, Mercer J, Bennett M. DNA damage and repair in atherosclerosis. Cardiovasc Res. 2006;71:259-268.
9. Busse R, Fleming I. Vascular endothelium and blood flow. Handb Exp Pharmacol. 2006;176:43-78.
10. Nordestgaard BG, Tybjderg-Hansen A. IDL, VLDL, chylomicrons and atherosclerosis. Eur J Epidemiol. 1992;8:92-98.
11. Mamo JCL, Wheeler JR. Chylomicrons or their remnants penetrate rabbit thoracic aorta as efficiently as smaller macromolecules including low density lipoprotein, high density lipoprotein and albumin. Coron Artery Dis. 1994;5:695-705.
12. Proctor SD, Mamo JCL. Retention of fluorescence-labelled chylomicron remnants within the intima of the arterial wall. Eur J Clin Invest. 1998;28:497-503.
13. Stender S, Zliversmit DB. Transfer of plasma lipoprotein components and of plasma proteins into aortas of cholesterol-fed rabbits: molecular size as a determinant of plasma lipoprotein influx. Arteriosclerosis. 1981;1:38-49.
14. Nordestgaard BG, Zilversmit DB. Large lipoproteins are excluded from the arterial wall in diabetic cholesterol fed rabbits. J Lipid Res. 1988;29:1491-1500.
15. Nordestgaard BG, Wootton R, Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler Thromb Vasc Biol. 1995;15:534-542.
16. Shaikh M, Wootton R, Nordestgaard BG, et al. Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans. Arterioscler Thromb. 1991;11:569-577.
17. Skålén K, Gustafsson M, Rydberg EK, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature. 2002;417:750-754.
18. Leitinger N. Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr Opin Lipidol. 2003;14:421-430.
19. Patel S, Celermajer DS. Assessment of vascular disease using arterial flow mediated dilatation.Pharmacol Rep. 2006;58:3-7.
20. Mallika V, Goswami B, Rajappa M. Atherosclerosis pathophysiology and the role of novel risk factors: a clinicobiochemical perspective. Angiology. 2007;58:513-522.
21. Marchesi S, Lupattelli G, Siepi D, et al. Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol. 2000;36:617-621.
22. Marchesi S, Lupattelli G, Lombardini R, et al. Effects of fenofibrate on endothelial function and cell adhesion molecules during postprandial lipemia in hypertriglyceridemia. J Clin Pharm Ther. 2003;28:419-424.
23. Lupattelli G, Marchesi S, Lombardini R, et al. Mechanisms of high-density lipoprotein cholesterol effects on the endothelial function in hyperlipemia. Metabolism. 2003;52:1191-1195.
24. Pirro M, Schillaci G, Paltriccia R, et al. Increased ratio of CD31+/CD42- microparticles to endothelial progenitors as a novel marker of atherosclerosis in hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2006;26:2530-2535.
25. Lehmann ED, Hopkins KD, Gosling RG. Aortic compliance measurements using Doppler ultrasound: in vivo biochemical correlates. Ultrasound Med Biol. 1993;19:683-710.
26. Wilkinson IB, Prasad K, Hall IR, et al. Increased central pulse pressure and augmentation index in subjects with hypercholesterolemia. J Am Coll Cardiol. 2002;39:1005-1011.
27. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37:1236-1241.
28. Pirro M, Schillaci G, Mannarino MR, et al. Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia. Nutr Metab Cardiovasc Dis. 2007;17:436-441.
29. Cameron JD, Jennings GL, Dart AM. The relationship between arterial compliance, age, blood pressure and serum lipid levels. J Hypertens. 1995;13:1718-1723.
30. Scalia R, Appel JZ 3rd, Lefer AM. Leukocyte-endothelium interaction during the early stages of hypercholesterolemia in the rabbit: role of P-selectin, ICAM-1, and VCAM-1. Arterioscler Thromb Vasc Biol. 1998;18:1093-1100.
31. Raison J, Rudnichi A, Safar ME. Effects of atorvastatin on aortic pulse wave velocity in patients with hypertension and hypercholesterolemia: a preliminary study. J Hum Hypertens. 2002;16:705-710.
32. Pirro M, Schillaci G, Savarese G, et al. Low-grade systemic inflammation impairs arterial stiffness in newly diagnosed hypercholesterolemia. Eur J Clin Invest. 2004;34:335-341.
33. Pirro M, Schillaci G, Savarese G, et al. Attenuation of inflammation with short-term dietary intervention is associated with a reduction of arterial stiffness in subjects with hypercholesterolemia. Eur J Cardiovasc Prev Rehabil. 2004;11:497-502.
34. Yuan G, Zhou L, Tang J, et al. Serum CRP levels are equally elevated in newly diagnosed type 2 diabetes and impaired glucose tolerance and related to adiponectin levels and insulin sensitivity. Diabetes Res Clin Pract. 2006;72:244-250.
35. Ohsawa M, Okayama A, Nakamura M, et al. CRP levels are elevated in smokers but unrelated to the number of cigarettes and are decreased by long-term smoking cessation in male smokers. Prev Med. 2005;41:651-656.
36. Schillaci G, Pirro M, Gemelli F, et al. Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures. J Hypertens. 2003;21:1841-1846.
37. Pirro M, Siepi D, Lupattelli G, et al. Plasma C-reactive protein in subjects with hypo/hyperalphalipoproteinemias. Metabolism. 2003;52:432-436.
38. Paulsson G, Zhou X, Törnquist E, et al. Oligoclonal T cell expansions in atherosclerotic lesions of apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2000;20:10-17.
39. Zhou X, Robertson AK, Hjerpe C, et al. Adoptive transfer of CD4+ T cells reactive to modified low-density lipoprotein aggravates atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26:864-870.
40. Zhou X, Robertson AK, Rudling M, et al. Lesion development and response to immunization reveal a complex role for CD4 in atherosclerosis. Circ Res. 2005;96:427-434.
41. Vaudo G, Marchesi S, Gerli R, et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis. 2004;63:31-35.
42. Gerli R, Schillaci G, Giordano A, et al. CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation. 2004;109:2744-2748.
43. Vaudo G, Bocci EB, Shoenfeld Y, et al. Precocious intima-media thickening in patients with primary Sjögren's syndrome. Arthritis Rheum. 2005;52:3890-3897.
44. Pirro M, Bergeron J, Dagenais GR, et al. Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men. Arch Intern Med. 2001;161:2474-2480.
45. St-Pierre AC, Cantin B, Bergeron J, et al. Inflammatory markers and long-term risk of ischemic heart disease in men A 13-year follow-up of the Quebec Cardiovascular Study. Atherosclerosis. 2005;182:315-321.
46. Pawlik A, Ostanek L, Brzosko I, et al. The expansion of CD4+CD28- T cells in patients with rheumatoid arthritis. Arthritis Res Ther. 2003;5:210-213.
47. Corretti MC, Anderson TJ, Benjamin EJ, et al. International Brachial Artery Reactivity Task Force.Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39: 257-265.
48. Boos CJ, Lip GY, Blann AD. Circulating endothelial cells in cardiovascular disease. J Am Coll Cardiol. 2006;48:1538-1547.
49. Jimenez JJ, Jy W, Mauro LM, et al. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb Res. 2003;109:175-180.
50. Xu Q. The impact of progenitor cells in atherosclerosis. Nat Clin Pract Cardiovasc Med. 2006;3:94-101.
51. Wassmann S, Werner N, Czech T, et al. Improvement of Endothelial Function by Systemic Transfusion of Vascular Progenitor Cells. Circ Res. 2006;99:74-83.
52. Op den Buijs J, Musters M, Verrips T, et al. Mathematical modeling of vascular endothelial layer maintenance: the role of endothelial cell division, progenitor cell homing, and telomere shortening. Am J Physiol Heart Circ Physiol. 2004;287:2651-2658.
53. Xu Q. Progenitor cells in vascular repair. Curr Opin Lipidol. 2007; 18:534-539.
54. Pirro M, Schillaci G, Menecali C, et al. Reduced number of circulating endothelial progenitors and HOXA9 expression in CD34+ cells of hypertensive patients. J Hypertens. 2007;25:2093-2099.
55. Pirro M, Schillaci G, Bagaglia F, et al. Microparticles derived from endothelial progenitor cells in patients at different cardiovascular risk. Atherosclerosis. 2007 Aug 24; [Epub ahead of print].
56. Magli MC, Largman C, Lawrence HJ. Effects of HOX homeobox genes in blood cell differentiation. J Cell Physiol. 1997;173:168-177.
57. Sauvageau G, Lansdorp PM, Eaves CJ, et al. Differential expression of homeobox genes in functionally distinct CD34+ subpopulations of human bone marrow cells. Proc Natl Acad Sci U S A. 1994;91:12223-12227.
58. Ferrell CM, Dorsam ST, Ohta H, et al. Activation of stem-cell specific genes by HOXA9 and HOXA10 homeodomain proteins in CD34+ human cord blood cells. Stem Cells. 2005;23:644-655.
59. Patel CV, Sharangpani R, Bandyopadhyay S, et al. Endothelial cells express a novel, tumor necrosis factor-alpha-regulated variant of HOXA9. J Biol Chem. 1999;274:1415-1422.
60. Bruhl T, Urbich C, Aicher D, et al. Homeobox A9 transcriptionally regulates the EphB4 receptor to modulate endothelial cell migration and tube formation. Circ Res. 2004;94:743-751.
61. Rossig L, Urbich C, Bruhl T, et al. Histone deacetylase activity is essential for the expression of HoxA9 and for endothelial commitment of progenitor cells. J Exp Med. 2005;201:1825-1835.